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sis. Late-stage diagnosis was associated with lower median income and lower
provider-to-case ratio. Among all comorbidity conditions, presence of congestive
heart failure, paralysis, renal failure, metastatic cancer, coagulation deficiency,
weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemias,
alcohol abuse, pneumococal pneumonia, protein calorie malnutrition, distur-
bances of amino acidmetabolism, brain and other neurological disorders were risk
factors of late-stage diagnosis. CONCLUSIONS: Overall, late-stage diagnosis was
associated with factors that suggest lack of access to care. Although comorbidity is
often associated with increased health care utilization, the association of comor-
bidity with late-stage prostate cancer diagnosis suggests that individuals with sig-
nificant comorbiditymaynot be offered routine prostate cancer screening, and that
focus is directed toward management of presenting health problems rather than
routine cancer screening.
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EFFECT OF TREATMENT DELAYS ON LATE-STAGE PROSTATE CANCER
SURVIVAL
Adunlin GB, Xiao H, Ali AA
Florida A&M University, Tallahassee, FL, USA
OBJECTIVES: To examine whether delay in receiving treatment for late-stage pros-
tate cancer were related to adverse survival outcomes. METHODS: The Florida
Cancer Data Systemwas used to extract information onmen diagnosed with pros-
tate cancer with their demographics, primary health insurance payer at diagnosis,
treatment and all-cause death. Census-tract level socioeconomic status was ex-
tracted from Census 2000 and linked to cancer data. Comorbidity following Elix-
hauser Index and County-level provider-to-case ratio were computed. Overall sur-
vival wasmeasured as the number of days between initiation of first treatment and
death? Descriptive statistics were performed. Log-rank test was conducted to eval-
uate the relationship between predictor variables and survival. Kaplan–Meier esti-
mation was used to generate survival curves. Cox proportional hazards regression
model was used for to produce hazard ratios (HRs) and 95% confidence intervals
after controlling for covariates. RESULTS: Between October 1, 2001 and December
31, 2007, 10330 men, average age of 69 had complete vital status, date of treatment
and survival time greater than zerowere diagnosedwith late-stage prostate cancer
in Florida. Of these, 3331 (32 %) died. Themedianswere 286 days for survival and 39
days between the date of diagnosis and initiation of first treatment. Treatment
delay was more likely to increase survival. Compare to patients in active surveil-
lance, those receiving other treatment options had an increased overall survival.
Patients with comorbidities, diagnosed at older age, or uninsured were more likely
to haveworse survival. Living in a census tract with higher educational attainment
was associated with better overall survival. CONCLUSIONS: Further investigation
is needed to understand the reasons for disparity in prostate cancer survival so that
interventions can be implemented to increase prostate cancer screening. The as-
sociation between changes in patterns of care, and treatment delay need to be
elucidated.
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OBJECTIVES: To assess clinical characteristics and national charges for maternal
hospitalizations and complications associated with cancers during pregnancy in
the United States. METHODS: This population-based retrospective study of inpa-
tient preterm complications or delivery and economic burden associatedwith can-
cer diagnosed during pregnancy utilized Agency for Healthcare Research andQual-
ity (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide Inpatient
Sample (NIS) data from 2005-2009. Inclusion criteria included 18 years, any ma-
ternal diagnoses or procedures on record, and any diagnosis of cancer. Descriptive
analyses were conducted to report the most common forms of cancer, complica-
tions of pregnancy, and comorbidities. Generalized linear models including multi-
variate logistic and gamma regressions were employed to assess outcomes of pre-
term births and charges, respectively, based upon patient demographics, primary
payer, hospital characteristics, length of stay, Elixhauser comorbidities, preterm
labor, abnormalities in fetal heart rate/rhythm, and pre-eclampsia/eclampsia.
RESULTS: Overall, 14,190 inpatient cancer discharges in pregnant adults from
2005-2009 were observed. The mean maternal age was 30.36.5 years, with an
average length of stay being 5.07.8 days. The national bill summed to $434 mil-
lion, averaging $31,366 (71,765) per case. The most common cancers were Hodg-
kin’s disease and other lymphomas (27%), breast cancer (15%), leukemias (14%),
genitourinary cancers (14%), and thyroid/endocrine cancers (7%). Some 2,846 full-
term births and 2,140 premature births occurred; 321 inpatient fetal deaths/mis-
carriages were reported. In cases involving births, regression analyses found that
metastatic cancer, solid tumors, and pre-eclampsia/eclampsia were significantly
(p0.05) associated with preterm delivery. Increases in total charges were signifi-
cantly associatedwithmetastatic cancer, chronic blood loss anemia, hypertension,
and fluid/electrolyte disorders. CONCLUSIONS: Some 4986 births were observed
among pregnant adults with cancer during 2005-2009, with a large proportion in-
volving premature delivery. Continued research is warranted concerning theman-
agement and long-term implications of cancer and its treatment upon both moth-
ers and their surviving children.
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OBJECTIVES: Spending on pharmaceuticals as a proportion of total health care
spending is increasing. It is unclear, however, if this increase is translating into
increases in QALYs relative to standard care over time. Our objectives were to
evaluate incremental QALY gains reported in cost-utility studies published from
2000 through 2010; and to compare the findings for cancer and non-cancer related
pharmaceuticals.METHODS:We used the Tufts Medical Center Cost-Effectiveness
Analysis Registry (www.cearegistry.org) to identify cost-utility ratios for pharma-
ceuticals published from 2000- 2010. We considered incremental QALY gains, pub-
lication year, and source of study funding (drug manufacturer or other), for three
sets of analyses: all pharmaceuticals (n2277); cancer-related pharmaceuticals
(n235); and non-cancer related pharmaceuticals (n2042). We used multivariate
linear regression to evaluate the relationship between incremental QALY gains
(dependent variable) with study publication year (independent variable). We re-
garded p values below the 0.05 level of significance as statistically significant and
values between 0.05-0.1 as weakly significant. RESULTS: Adjusting for source of
study funding, in terms of the relationship between incremental QALY gains and
study publication year: for all pharmaceuticals, the estimated coefficient for pub-
lication year was negative (-0.015; p0.082); for non-cancer related pharmaceuti-
cals the estimated coefficient for publication year was negative, (-0.022, p0.017);
and, for cancer related pharmaceuticals, the estimated coefficient for publication
year was positive (0.069, p0.001). CONCLUSIONS: The results suggest that, in
contrast to the effectiveness of non-cancer related pharmaceuticals; the effective-
ness of cancer-related pharmaceuticals show increasing gains over time. That is,
incremental QALY gains for cancer-related drugs are increasing.
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OBJECTIVES: The aim of this study was to determine survival rate, life expectancy,
quality-adjusted life expectancy (QALE), and prognostic factors of cancer patients
of different organ-systems undergoing prolonged mechanical ventilation (PMV).
METHODS: We used data from the National Health Insurance Research Database
(NHIRD) of Taiwan, year of 1998 to 2007, and linked with the National Mortality
Registry to ascertain the mortality. A random sample of this population was per-
formed, and subjects who had continuously undergonemechanical ventilation for
longer than 21 days were enrolled in this study. We linked our dataset with the
registry of cancer under catastrophic illnesses of NHIRD. The life expectancies of
different organ-systems were estimated using a semi-parametric method with
assuming constant excess hazard and barrowing survival function of general pop-
ulation from the vital statistics of Taiwan. Multivariate proportional hazard model
was constructed to assess the effect of different prognostic factors, including age,
sex, organ-systems, comorbidities, hospital levels, and metastasis. Quality of life
data were taken from a sample of 142 patients under PMV and measured with
EQ-5D, which were classified into partial and poor cognitions. RESULTS: The anal-
ysis of 5138 cancer patients undergoing PMV revealed themedian survival was 1.37
months with a one-year survival rate of 14.3%. Head and neck cancer patients
seemed to survive the longest. The overall life expectancy was 1.21 years with
estimated QALE ranged from 0.16 to 0.36 quality-adjusted life years for patients
with poor and partial cognitions, respectively. Metastatic cancer status, cancer
type of lung and liver significantly predict a shorter survival independently.
CONCLUSIONS:Cancer patientswith PMVhad a poor long termoutcome. Palliative
care should be considered early in these patients with such a condition, especially
when metastasis occurred.
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EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS
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OBJECTIVES: To examine the comparative effectiveness of primary androgen de-
privation therapy (PADT) and radical prostatectomy (RP).METHODS:Male patients
with localized prostate cancer (T1-T2, N0, M0) were identified in the SEER-Medicare
database from January 1998 to December 2007. Patients were 66-74 years old, with-
out other documented cancers, and had PADT initiation or RP within 6 months
after the first recorded diagnosis of prostate cancer in the dataset. PADT-treated
patients were 1:1 matched to the RP-treated patients via propensity score (PS)
matching. The overall survival from diagnosis to death was analyzed using Cox
proportional hazardmodels; prostate cancer specific survival examined using Fine
and Gray competing riskmodeling. The independent regression variables included
age at diagnosis, race, marital status, census regions, urban residence, clinical
cancer stage, Gleason score, prostate specific antigen level, Charlson comorbidity
index, calendar year at diagnosis, andhospitalization (yes or no), surgery (yes or no)
and outpatient visit (yes or no) during one year baseline period. RESULTS: The
PS-matched sample size was 3432 with mean age of 66.0 years. The baseline char-
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